WO2002080966A2 - Verfahren zur herstellung eines autologen antikörpers enthaltenden impfstoffes - Google Patents
Verfahren zur herstellung eines autologen antikörpers enthaltenden impfstoffes Download PDFInfo
- Publication number
- WO2002080966A2 WO2002080966A2 PCT/AT2002/000091 AT0200091W WO02080966A2 WO 2002080966 A2 WO2002080966 A2 WO 2002080966A2 AT 0200091 W AT0200091 W AT 0200091W WO 02080966 A2 WO02080966 A2 WO 02080966A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- ligands
- antibody
- vaccine
- autologous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- non-immunogenic antigens are so-called "self-antigens", ie structures that the immune system recognizes as the body's own substances. Immunization with such antigens usually does not result in a specific immune response. In the case of tumor-associated antigens, the fact that these antigens are actually "self-antigens" is one of the greatest difficulties in developing a potent vaccine.
- Active immunization is also used to protect against toxic substances (e.g. bacterial toxins). If the toxins are to be used as a vaccine, they must first be weakened or inactivated. Such inactivation can affect the effectiveness of the immune response. Anti-idiotypic antibodies as vaccines that mimic toxins have been proposed (Int J Clin Lab Res (1992) 22:28; Clin Exp Immunol. (1992) 89: 378; Immunopharmacology (1993) 26: 225).
- Active immunization for modulation can currently be performed with certain antigens, which may either be too toxic or potentially infectious, or may be non-immunogenic.
- a partial solution to this problem is the use of anti-idiotypic antibodies for immunization.
- efficient treatment strategies for autoimmune diseases, allergies and similar complaints are to be created.
- B evorzugt the antibody-containing body fluids, of course, blood, serum, lymphatic fluid, Cere- are brospinalfactkeit, colostrum, mucosal body fluids such as vaginal or nasal discharge, malignant effusions, feces or urine, but it can just as well autologous cells or tissue preparations obtained by biopsy can be processed with a variety of methods known per se for liquids containing antibodies to be used according to the invention. Above all those body fluids with a particularly high antibody content are used according to the invention as starting materials, with human serum or plasma being of course particularly preferred.
- ligands can be selected which recognize a certain group of antibody fragments or chains, for example at least parts of the lambda or kappa chains, Fc or Fab fragments. Likewise suitable ligands selectively bind not only antibodies but also corresponding isotypes or paraglobulins.
- Autologous vaccines produced according to the invention which contain antibodies which occur in connection with B-cell lymphoma contain in particular only certain subclasses or fractions of the serum fraction containing IgG in order to ensure the targeted immune response.
- antibodies or antibody fragments such as e.g. Fc or Fab fragments can be used.
- ligands can also be other substances to which immunoglobulins can bind, for example ligands for the chromatographic purification of immunoglobulins, affinity peptides, affinity polypeptides, proteins such as protein A or protein G, or ionic structures which are also used, for example, for ion exchange chromatography.
- the suitable immobilized ligands care is usually taken to ensure that undesired bleeding of the ligands or of ligand-antibody complexes into the isolated antibody fraction obtained is avoided.
- serial cleaning of the antibodies may also be appropriate in order to separate any contaminants from the immobilized ligands. Bleeding out of the material can also be advantageous if certain ligand-antibody complexes are desired in the preparation.
- a storage-stable embodiment of the autologous vaccine produced according to the invention is particularly desirable if the patient is to be immunized several times with the same preparation at intervals.
- the administration of freshly produced vaccines can have the advantage that changes in the immune system are taken into account and the occurrence of escape mutants, for example of antibody-producing cells or infectious agents, can be largely prevented.
- the simple processing of the antibodies obtained into a vaccine is suitable for this, which in the best case can be done on site.
- the vaccine produced according to the invention can be used immediately after taking blood within one working day, or even during patient treatment.
- Another embodiment of the method according to the invention relates to the depletion of components of the body fluid that are undesirable in the vaccine.
- ligands can be chosen which do not selectively bind certain antibodies, but which do, however, have accompanying substances in order to then obtain the specific antibodies from the unbound fraction.
- individuals are understood to mean individual human or animal organisms which have body fluids or tissues which contain antibodies.
- the production according to the invention is of course preferably used in vertebrates, particularly preferably mammals, in particular humans.
- the agent b) comprises substances or solutions of substances for washing or cleaning or desorbing the antibodies. These include wash buffers and / or elution buffers.
- a formulation agent including a possible adjuvant is also provided in the set according to the invention, provided that this is not already included as b) in the agent for obtaining the antibodies.
- antibodies can be adsorbed on a sparingly soluble aluminum compound, whereupon they can be washed in a simple manner and in a single device, re-buffered and packaged into a finished vaccine which already contains the aluminum compound as an adjuvant. Then namely only a single means for obtaining the antibodies and processing the vaccine instead of separate components b) and c) in the set according to the invention needed. Otherwise, additional aids, such as washing and buffering substances, can be provided in the set.
- Suitable ligands can also be attached to magnetic beads, which can be easily located or oriented or positioned using a magnet.
- a specific ligand is bound to ferromagnetic particles, for example, and placed in a sterile container to hold the body fluid. If a magnetic transport part or rod is also stored in the container, the particles on which the antibodies are bound from the body fluid can be collected on the transport part by switching the magnet on and off, for example by means of electrical pulses for actuating an electromagnet. The particles can then be separated, preferably while maintaining the magnetic field. The magnetic field can be removed again during a washing process or antibody desorption. Afterwards, immobilization of the particles on the magnets is again expedient in order to separate or obtain the washing solution or the desorbed antibodies.
- the first container comprises the ligands required for the adsorption of the antibodies, bound to ferromagnetic particles (“beads”).
- Beads include activated porous glass beads such as Prosep (Millipore, Durham, UK), Dynabeads (Deutsche Dynal GmbH, Hamburg, Germany) and the same material from Miltenyi (Bergisch Gladbach, Germany).
- An adsorption buffer is also placed in this container or separately. Human serum is introduced via a septum.
- the antibodies can be eluted in a separate elution vessel with elution buffer, into which the loaded beads are placed. After elution of the antibodies, the "beads" are separated by immobilization on the transport part and removal of the same from the solution. Then a formulation agent is added through a septum. The formulated solution is introduced into a syringe and is ready for use on the patient.
- the individual containers are each equipped with one or more septa for the transfer of solutions or suspensions, as well as frits for phase separation.
- the set is made available as a container which contains the ligands and the agents b) and c).
- this agent may be advantageous to use this agent together with the ligands in a formulation.
- a carrier of ligands can be selected that is also used for the production of antibodies and has an adjuvant effect.
- a carrier is a poorly soluble aluminum compound such as AluGel or aluminum hydroxide.
- Antibodies from the liquids of individuals to the ligands can be bound in a mixed bed ("batchwise") or in a flow-through method. Immunoaffinity cleaning can be carried out automatically on a chromatography apparatus or by means of a manual process; however, it is also conceivable that the method is carried out manually, automatically or semi-automatically using a simple device which contains the immobilized ligands.
- the desired antibodies can essentially be separated from the body from undesired other substances. It is conceivable that this task can be accomplished by separation processes other than immunoaffinity purification, such as described above, can be solved, such as by reacting ligands with the antibodies and then separating the specific immune complexes from the substances not complexed with the ligands.
- the antibodies can also be bound to or obtained from the ligands in the liquid phase, colloidal solution, emulsion or by so-called "immune affinity partitioning".
- the present invention also relates to a method for producing an autologous antibody-containing vaccine, characterized by the following steps:
- the preparation of xenografting is another area of application to prevent possible intolerance reactions due to the graft.
- High titers of natural antibodies against the well-known ⁇ -gal epitope / as found in serum in humans are partly responsible for acute A bommeungsre force against xenografts or allografts.
- These natural anti- ⁇ -Gal antibodies are formulated with the aid of the method according to the invention into a vaccine and administered to the patient who is being prepared for the transplantation of tissue, bone marrow or stem cells.
- the downregulation of the anti-Gal activity should help to avoid rejection reactions.
- Lowering the titer of the circulating anti- ⁇ -Gal antibodies by immunization with autologous anti- ⁇ -Gal antibodies should allow a significant increase in the survival time of xenografts.
- toxin-specific antibodies can be used as ligands.
- such antibodies are available as monoclonal.
- two or more ligands with different specificity can of course also be immobilized on the solid support with the present method and in this way antibodies can be obtained in preparations with specificities which are enriched or depleted in terms of several binding properties (antibodies with different specificity).
- the serial connection of several immunoadsorption steps with different specificities is preferred in the production of multi-specific vaccines according to the present invention.
- Particularly preferred ligands according to the present invention are autoantigens such as e.g. double-stranded DNA to treat patient-specific antibodies against ds-DNA from patients with systemic lupus erythematosus (SLE).
- SLE systemic lupus erythematosus
- Factor VIII or parts thereof can be used as a ligand to isolate strongly factor VIII-binding antibodies from an individual and to down-regulate the pathogenic anti-factor VIII reactivity of a patient with the vaccine formulated therefrom (Semin. Thromb. Hemost. (2000) 26: 151)
- Individual antibodies can be purified from patients with myasthenia gravis by immunoaffinity purification with acetylcholine receptor or parts thereof (Proc. Natl. Acad. Sci. USA (1993) 90: 8747), which according to the invention can be vaccinated back to the same patient as an autologous vaccine.
- Insulin as a ligand can be used in the production of an autologous vaccine against autoimmune diabetes (type insulin-dependent diabetes mellitus) (Diabetes Metab. Res. Rev. (2000): 16: 338).
- Myelin basic protein (MBP) or parts thereof can be used as a ligand in the production of an autologous vaccine for multiple sclerosis patients or patients with other immunologically related neurological disorders (J. Neuroimmunol. (2001) 113: 163).
- gangliosides can be used as a ligand (in patients with Guillain-Barre syndrome (Intern. Med. (1997) 36: 599) and other neuropathies.
- Another preferred ligand according to the present invention is an anti-human IgE antibody with which very specific IgE fractions can be purified and which in turn can be administered to the patient in a suitable, immunogenic form in order to inhibit specific gE-producing cells in the patient , Nature- parts of specific anti-IgE antibodies, provided that they still have the desired specificity, can also be used as a ligand.
- Antibody derivatives that can be produced according to known chemical or biochemical methods, e.g. Antibodies amidated with fatty acids on free amino functions in order to increase the lipophiles for incorporation into liposomes.
- the term also includes products that can be produced by chemically coupling antibodies or antibody fragments with molecules that can enhance the immune response, such as e.g. Tetanus toxoid, Pseudomonas exotoxin, derivatives of Lipid A, GM-CSF, IL-2, IL-12, C3d.
- working up the antibody eluates accordingly includes adding a substance selected from the group of adjuvants, in particular aluminum-containing adjuvants, lipopolysaccharide derivatives, Bacillus Calmette Guerin, liposomes or QS-21 ( further preferred adjuvants are described, inter alia, in Singh et al., Nat. Biotechnol. 17 (1999), pages 1075-1081), immunostimulating cells, in particular dendritic cells or other antigen-presenting cells, active agents, preferably cytokines, in particular granulocyte-macrophage-stimulating factor, formulation auxiliaries, in particular buffer substances, stabilizers or solubilizers, or mixtures of these substances.
- adjuvants in particular aluminum-containing adjuvants, lipopolysaccharide derivatives, Bacillus Calmette Guerin, liposomes or QS-21 ( further preferred adjuvants are described, inter alia, in Singh et al., Nat. Biotechnol. 17 (19
- physico-chemical parameters such as ionic strength, ion composition, pH, type and amount of the active surface in the mixture are responsible for the denaturation of a protein.
- Conditions are known and can easily be optimized by the person skilled in the art for any eluate in which the antibodies are not or not completely denatured and / or other effects, such as weaker desorption from the surface of the adjuvant, can be used.
- Another advantage of such a formulation is the possible increased immunogenicity of the antibodies, since the heating can cause the antibodies to be at least partially denatured.
- This increased antigenicity can increase the immunogenicity in particular in the case of proteins which the immune system would recognize as their own proteins.
- the present invention also relates to pharmaceutical compositions containing antibodies obtained from animal body fluids containing antibodies by immunoaffinity purification for use as autologous vaccines.
- This example is intended to illustrate that it is possible to boost the immune system against any protein (in this case Bovines Serum albumin, BSA) to be specifically modulated.
- BSA Bovines Serum albumin
- the autologous vaccine for the first group was prepared by purifying rabbit serum immunoglobulin on an affinity chromatography column (rabbit anti-BSA immobilized on Sepharose).
- the autologous vaccine for the second group was prepared by purifying rabbit serum immunoglobulin over another affinity chromatography column (Sepharose without specific ligands).
- Serum samples were serially diluted (in 2% dry milk / PBS). The sample dilutions (100 ⁇ l / well) were incubated for 1 hour at 37 ° C. cubed. A dilution series of the polyclonal rabbit anti-BSA serum, which had been used for affinity purification, served as positive control and as standard for a quantitative evaluation of the ELISA. After washing, the enzyme conjugate (Anti rabbit Ig HRP (Nordic Immunology, # 4694)) was applied in an appropriate dilution (1: 1000 dilution buffer) (100 ⁇ l / well). After an incubation of 30 min.
- Blocking buffer A 5% fetal calf serum (heat inactivated) in PBS
- the antibody fraction thus obtained was tested in an ELISA for binding to antibody HE2 (which was used as a ligand for affinity purification): 100 ⁇ l aliquots of the mouse IgG2a antibody used for affinity purification (antibody HE2; solution with 10 ⁇ g / l in binding buffer) incubated in the wells of a micro titer plate for 1 hour at 37 ° C. After washing the plate six times with washing buffer A, 200 ⁇ l of blocking buffer A were added in each case and incubated at 37 ° C. for 30 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK1173-2003A SK11732003A3 (sk) | 2001-03-23 | 2002-03-20 | Spôsob výroby očkovacej látky |
MXPA03008587A MXPA03008587A (es) | 2001-03-23 | 2002-03-20 | Metodo para producir una vacuna. |
JP2002579005A JP2004524369A (ja) | 2001-03-23 | 2002-03-20 | ワクチンの製造方法 |
HU0303638A HUP0303638A3 (en) | 2001-03-23 | 2002-03-20 | Method for producing a vaccine |
CA002441499A CA2441499A1 (en) | 2001-03-23 | 2002-03-20 | Method for producing a vaccine |
EP02706509A EP1370289A2 (de) | 2001-03-23 | 2002-03-20 | Verfahren zur herstellung eines autologen antikörpers enthaltenden impfstoffes |
PL02363720A PL363720A1 (en) | 2001-03-23 | 2002-03-20 | Method for producing a vaccine |
BR0208641-7A BR0208641A (pt) | 2001-03-23 | 2002-03-20 | Método para produzir uma vacina contendo anticorpos autólogos e uso da mesma |
US10/472,876 US20040191242A1 (en) | 2001-03-23 | 2002-03-20 | Method for producing a vaccine |
NO20034145A NO20034145L (no) | 2001-03-23 | 2003-09-17 | Fremgangsmåte til å produsere en vaksine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0047001A AT410636B (de) | 2001-03-23 | 2001-03-23 | Verfahren zur herstellung eines impfstoffes |
ATA470/2001 | 2001-03-23 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002080966A2 true WO2002080966A2 (de) | 2002-10-17 |
WO2002080966A8 WO2002080966A8 (de) | 2003-01-23 |
WO2002080966A3 WO2002080966A3 (de) | 2003-09-12 |
Family
ID=3674741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AT2002/000091 WO2002080966A2 (de) | 2001-03-23 | 2002-03-20 | Verfahren zur herstellung eines autologen antikörpers enthaltenden impfstoffes |
Country Status (13)
Country | Link |
---|---|
US (1) | US20040191242A1 (de) |
EP (1) | EP1370289A2 (de) |
JP (1) | JP2004524369A (de) |
CN (1) | CN1522155A (de) |
AT (1) | AT410636B (de) |
BR (1) | BR0208641A (de) |
CA (1) | CA2441499A1 (de) |
HU (1) | HUP0303638A3 (de) |
MX (1) | MXPA03008587A (de) |
NO (1) | NO20034145L (de) |
PL (1) | PL363720A1 (de) |
SK (1) | SK11732003A3 (de) |
WO (1) | WO2002080966A2 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002096455A2 (de) * | 2001-06-01 | 2002-12-05 | Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag | Verwendung von polyklonalen immunglobulinen als impfstoff |
WO2005090403A2 (en) * | 2004-03-12 | 2005-09-29 | Biovest International, Inc. | Method and apparatus for antibody purification |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2474627B1 (de) * | 2007-02-21 | 2015-05-20 | Oslo Universitetssykehus HF | Neue Krebsmarker |
EP2236520A1 (de) | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilisierungszusammensetzung für immobilisierte Biomoleküle |
WO2022103871A1 (en) * | 2020-11-10 | 2022-05-19 | Wyomingv Immune, Inc. | Therapeutic compositions for the treatment of covid-19 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996015153A1 (en) * | 1994-11-16 | 1996-05-23 | Baxter International Inc. | Human antibodies to t-cell receptor peptides and methods for their preparation |
DE19538641A1 (de) * | 1995-10-05 | 1997-04-17 | Privates Inst Bioserv Gmbh | Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung |
WO1998026086A1 (en) * | 1996-12-11 | 1998-06-18 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4436558A1 (de) * | 1994-10-13 | 1996-04-18 | Vitorgan Arzneimittel Gmbh | Verfahren zur Herstellung von humanen Impfstoffen gegen allergieauslösende Substanzen |
US7022036B2 (en) * | 2003-05-21 | 2006-04-04 | Prototoy Llc | Electronic throw-and-catch game |
-
2001
- 2001-03-23 AT AT0047001A patent/AT410636B/de not_active IP Right Cessation
-
2002
- 2002-03-20 JP JP2002579005A patent/JP2004524369A/ja active Pending
- 2002-03-20 WO PCT/AT2002/000091 patent/WO2002080966A2/de active Application Filing
- 2002-03-20 BR BR0208641-7A patent/BR0208641A/pt not_active Application Discontinuation
- 2002-03-20 SK SK1173-2003A patent/SK11732003A3/sk not_active Application Discontinuation
- 2002-03-20 US US10/472,876 patent/US20040191242A1/en not_active Abandoned
- 2002-03-20 CN CNA028088387A patent/CN1522155A/zh active Pending
- 2002-03-20 EP EP02706509A patent/EP1370289A2/de not_active Withdrawn
- 2002-03-20 CA CA002441499A patent/CA2441499A1/en not_active Abandoned
- 2002-03-20 HU HU0303638A patent/HUP0303638A3/hu unknown
- 2002-03-20 PL PL02363720A patent/PL363720A1/xx not_active Application Discontinuation
- 2002-03-20 MX MXPA03008587A patent/MXPA03008587A/es not_active Application Discontinuation
-
2003
- 2003-09-17 NO NO20034145A patent/NO20034145L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996015153A1 (en) * | 1994-11-16 | 1996-05-23 | Baxter International Inc. | Human antibodies to t-cell receptor peptides and methods for their preparation |
DE19538641A1 (de) * | 1995-10-05 | 1997-04-17 | Privates Inst Bioserv Gmbh | Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung |
WO1998026086A1 (en) * | 1996-12-11 | 1998-06-18 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
Non-Patent Citations (5)
Title |
---|
DWYER D S ET AL: "NATURALLY OCCURRING ANTI-IDIOTYPIC ANTIBODIES IN MYASTHENIA GRAVIS PATIENTS" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, Bd. 301, Nr. 5901, 17. Februar 1983 (1983-02-17), Seiten 611-614, XP002927728 ISSN: 0028-0836 * |
LOSMAN M J ET AL: "Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, Bd. 88, Nr. 8, 15. April 1991 (1991-04-15), Seiten 3421-3425, XP002147167 ISSN: 0027-8424 * |
See also references of EP1370289A2 * |
VALDERRAMA R ET AL: "Treatment of experimental myasthenia with autologous idiotypes linked to muramyl dipeptide." CLINICAL AND EXPERIMENTAL IMMUNOLOGY. ENGLAND JUL 1988, Bd. 73, Nr. 1, Juli 1988 (1988-07), Seiten 123-127, XP001118740 ISSN: 0009-9104 * |
ZOUALI M ET AL: "Suppression of murine lupus autoantibodies to DNA by administration of muramyl dipeptide and syngeneic anti-DNA IgG." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES AUG 1985, Bd. 135, Nr. 2, August 1985 (1985-08), Seiten 1091-1096, XP002218883 ISSN: 0022-1767 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002096455A2 (de) * | 2001-06-01 | 2002-12-05 | Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag | Verwendung von polyklonalen immunglobulinen als impfstoff |
WO2002096455A3 (de) * | 2001-06-01 | 2003-12-24 | Igeneon Krebs Immuntherapie | Verwendung von polyklonalen immunglobulinen als impfstoff |
WO2005090403A2 (en) * | 2004-03-12 | 2005-09-29 | Biovest International, Inc. | Method and apparatus for antibody purification |
WO2005090403A3 (en) * | 2004-03-12 | 2006-05-04 | Biovest Int Inc | Method and apparatus for antibody purification |
Also Published As
Publication number | Publication date |
---|---|
SK11732003A3 (sk) | 2004-03-02 |
MXPA03008587A (es) | 2004-06-30 |
HUP0303638A2 (hu) | 2004-01-28 |
CA2441499A1 (en) | 2002-10-17 |
JP2004524369A (ja) | 2004-08-12 |
US20040191242A1 (en) | 2004-09-30 |
WO2002080966A3 (de) | 2003-09-12 |
CN1522155A (zh) | 2004-08-18 |
NO20034145L (no) | 2003-11-07 |
EP1370289A2 (de) | 2003-12-17 |
NO20034145D0 (no) | 2003-09-17 |
WO2002080966A8 (de) | 2003-01-23 |
BR0208641A (pt) | 2004-03-09 |
ATA4702001A (de) | 2002-11-15 |
PL363720A1 (en) | 2004-11-29 |
AT410636B (de) | 2003-06-25 |
HUP0303638A3 (en) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69927262T2 (de) | Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren | |
FI111336B (fi) | Menetelmä Staphylococcus epidermidis tyyppi I:n polysakkaridiantigeenin sisältävän rokotteen ja antigeeninvastaisen hyperimmunoglobuliinin valmistamiseksi | |
US8444974B2 (en) | Use of antibodies for the vaccination against cancer | |
DE69110877T2 (de) | Idiotypen-impfung gegen b-zell-lymphoma. | |
EP1229936B1 (de) | Verwendung von anti-idiotypischen antikörpern als impfstoffe gegen krebs | |
Yu et al. | Immunochemical properties of anti-Galα1–3Gal antibodies after sensitization with xenogeneic tissues | |
DE69833455T2 (de) | Verfahren und zusammensetzungen zur verstärkung der immunantwort und zur in-vitro herstellung von monoklonalen antikörpern (mabs) | |
AT410636B (de) | Verfahren zur herstellung eines impfstoffes | |
AT500650B1 (de) | Immunogener rekombinanter antikörper | |
EP1506012A1 (de) | Verwendung eines impfstoffes zur aktiven immunisierung gegen krebs | |
US20060018901A1 (en) | Use of antibodies in a very low dose for the vaccination against cancer | |
JP4777599B2 (ja) | ヒト抗胸腺細胞免疫グロブリンの製造方法 | |
EP1399185A2 (de) | Verwendung von polyklonalen immunglobulinen als impfstoff | |
RU2283666C2 (ru) | Средство для активации восстановления структуры и функции поврежденных тканей и органов | |
RU2287345C2 (ru) | Средство для стимуляции выработки фактора viii свертывания крови | |
CZ20032573A3 (cs) | Způsob výroby očkovací látky | |
RU2174408C2 (ru) | Препарат для профилактики и лечения дифтерии и способ его получения | |
JPH07116057B2 (ja) | 免疫増強剤及び強化抗原 | |
US20040265318A1 (en) | Use of antibodies for the vaccination against cancer | |
WO2003077943A2 (de) | Verfahren zur herstellung einer pharmazeutischen präparation durch adsorption an eine schwerlösliche aluminiumverbindung | |
GB2104527A (en) | Antigens as immunostimulant adjuvants | |
WO2001019388A1 (de) | Contactinhibin enthaltendes arzneimittel sowie arzneimittel, das gegen contactinhibin gerichtete antikörper enthält |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 528313 Country of ref document: NZ Ref document number: 2002706509 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11732003 Country of ref document: SK Ref document number: 2002240695 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002579005 Country of ref document: JP Ref document number: 2441499 Country of ref document: CA Ref document number: 898/MUMNP/2003 Country of ref document: IN Ref document number: PA/A/2003/008587 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-2573 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 090632002 Country of ref document: AT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028088387 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002706509 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-2573 Country of ref document: CZ |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 42/2002 UNDER (72, 75) REPLACE "DOBLHOFF-DIER" BY "DOBLHOFF- DIER, OTTO" |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10472876 Country of ref document: US |